OPK Opko Health Inc.

2
-0.03  -1%
Previous Close 2.03
Open 2.03
Price To Book 0.7
Market Cap 1,231,202,090
Shares 615,601,045
Volume 8,258,303
Short Ratio
Av. Daily Volume 4,686,078

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data March 21, 2019 met primary endpoint. Phase 3 trial planned.
OPK88003
Obesity and diabetes
Phase 2a trial planned for 2H 2018.
OPK88002
Pruritus in Stage 5 CKD patients undergoing dialysis
Phase 2a trial planned for 2H 2018.
OPK88001
Dravet Syndrome
Phase 2b trial to be initiated 2H 2017.
TT701 (selective androgen receptor modulator)
Benign Prostatic Hyperplasia (BPH)
Phase 2b trial suspension announced January 31, 2019.
OPK88004
Benign Prostatic Hyperplasia (BPH)
Phase 2 data due 2H 2020.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP
Adults - growth hormone deficiency
Phase 3 data due YE 2019.
hGH-CTP
Children - growth hormone deficiency
Announced June 21 2016 FDA Approval
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Phase 2 ongoing as of September 2017.
Factor VIIa-CTP
Hemophilia
Phase 3 to be initiated 1H 2018.
Fermagate Tablets
hyperphosphatemia in CKD patients on chronic hemodialysis
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV